Skip to main content
Equibles
RGNX logo

RGNX · REGENXBIO Inc. · Metrics

Track RGNX — free

Use RGNX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RGNX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$7.80 +0.18 (+2.31%) Play latest call Q3 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Going-concern doubt — flagged Nov 5, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These conditions raise substantial doubt about our ability to continue as a going concern within 12 months from the issuance date of our consolidated financial statements for the three and nine months ended September 30, 2026 included in this Quarterly Report on Form 10-Q.”
View the 10-Q filed Nov 5, 2026
Market Cap
$503.85M
Shares
66.12M
Volume · Nov 9 161.37K Avg daily vol (3M) 1.35M

RGNX metrics

88 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$7.62
Market cap
$503.85M

Price action

23 metrics
Price change (1W)
+5.8%
Price change (30D)
-5.6%
Price change (3M)
-28.9%
Price change (6M)
-27.8%
Price change (YTD)
-47.1%
Price change (1Y)
-31.8%
Trailing year
Price change (5Y)
-80.5%
52-week high
$15.98
52-week low
$5.65
Change from 52-week high
-52.3%
Change from 52-week low
+34.9%
Annualized volatility
91.8%
Annualized volatility (3M)
81.3%
Implied volatility (30D)
123.5%
IV rank (1Y)
36.5
IV percentile (1Y)
88.5
Beta
1.7
RSI (14D)
52.5
Price vs SMA 50
-2.4%
Price vs SMA 200
-15.3%
Avg volume (3M)
1.35M
Relative volume
0.9
Average dollar volume
$11.14M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
66.12M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
3.3×
reciprocal yield 30.5%
P / book
3.4
reciprocal yield 29.4%
FCF yield
-30.7%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-34.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-11-05

Profitability

9 metrics
Gross margin
—
Operating margin
-95.7%
Trailing 12 months
Net margin
-113.9%
Gross profit (TTM)
$49.76M
Operating profit (TTM)
−$147.27M
Net income (TTM)
−$175.23M
Trailing 12 months
Diluted EPS (TTM)
$-3.21
FCF margin
-100.6%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$2.89
Gross profit per diluted share (TTM)
$1.00
Operating profit per diluted share (TTM)
$-2.70
EBITDA per diluted share (TTM)
$-2.42
Net income per diluted share (TTM)
$-3.21
Operating cash flow per diluted share (TTM)
$-3.05
Free cash flow per diluted share (TTM)
$-3.10
Capital expenditures per diluted share (TTM)
$0.05
R&D per diluted share (TTM)
$4.24
Stock compensation per diluted share (TTM)
$0.62
Book value per share
$2.02

Growth

11 metrics
Revenue growth YoY
-69.2%
Year over year
Net income growth YoY
—
Revenue (TTM)
$153.91M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+26.3%
Year over year · more shares
Revenue CAGR (3Y)
+14.8%
Revenue CAGR (5Y)
+2.0%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-118.4%
Return on assets
-37.6%
Debt / equity
—
Current ratio
4.7
EBITDA (TTM)
−$132.27M
Free cash flow (TTM)
−$154.80M
Quick ratio
4.7
Interest coverage
-4.1
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$250.98M
Latest balance sheet
Cash & equivalents
$95.80M
Total assets
$466.04M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$152.10M
Capital expenditures (TTM)
$2.70M
R&D (TTM)
$234.04M
SG&A (TTM)
—
Stock compensation (TTM)
$34.16M
R&D / revenue
152.1%
Stock compensation / revenue
22.2%

Ownership (13F)

9 metrics
13F filers
169
13F filer change QoQ
-10
Institutional ownership
64.9%
Conviction holders (share of 13F filers)
1.2%
Crowding (high-turnover and private-fund holders)
29.5%
Private-fund adviser ownership
25.7%
Active holders' share change QoQ
-3.9%
Holder tenure
14.9
Price vs estimated holder cost
+25.6%

Ownership (registered funds)

1 metrics
Index-fund ownership
13.5%

Short interest

3 metrics
Short interest
15.2%
Latest settlement · 6.8 days to cover
Days to cover
6.8d
Short-squeeze score
84 / 100

Insider activity

2 metrics
Net insider buying (90D)
$949,381
Insider-sentiment score
87 / 100

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1590877 CUSIP 75901B107 13F (30d) 63 filings 51 filers Visit website Investor relations